The dopaminergic response in multiple system atrophy.
暂无分享,去创建一个
B Kleedorfer | A J Lees | A. Lees | C. Colosimo | A. Hughes | S. Daniel | S E Daniel | C Colosimo | B. Kleedorfer | A J Hughes | Andrew | Lees | A. J. Hughes | A. J. Lees | B. Kleedorfer | A. Hughes
[1] Y. Kuroiwa,et al. Failed levodopa therapy in striato-nigral degeneration. , 1971, Lancet.
[2] T. Chase,et al. Pathogenesis of dyskinesias in parkinson's disease , 1989, Annals of neurology.
[3] A. Rajput,et al. Levodopa efficacy and pathological basis of Parkinson syndrome. , 1990, Clinical neuropharmacology.
[4] A. Koeppen,et al. Striatonigral degeneration , 2004, Acta Neuropathologica.
[5] C. Goetz,et al. The pharmacology of olivopontocerebellar atrophy. , 1984, Advances in neurology.
[6] A. Rajput,et al. Striatonigral degeneration response to levodopa therapy. , 1972, Journal of the neurological sciences.
[7] C. Tanner,et al. Weekly drug holiday in Parkinson disease , 1981, Neurology.
[8] J. Kepes,et al. Parkinsonism due to a basal ganglia lacunar state , 1990, Neurology.
[9] Ward Cd,et al. Research diagnostic criteria for Parkinson's disease. , 1990 .
[10] C. Marsden,et al. Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism. , 1982, Journal of neurology, neurosurgery, and psychiatry.
[11] A. Gosset,et al. [Striatonigral degeneration associated with olivopontocerebellar atrophy. Anatomo-clinical study of 3 cases. Nosologic discussion]. , 1983, Revue neurologique.
[12] A. Lees,et al. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes , 1990, The Lancet.
[13] N. Quinn,et al. Multiple system atrophy--the nature of the beast. , 1989, Journal of neurology, neurosurgery, and psychiatry.
[14] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[15] M. Muenter,et al. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. , 1971, Mayo Clinic proceedings.
[16] J. Trotter. Striatonigral degeneration, Alzheimer's disease, and inflammatory changes , 1973, Neurology.
[17] R D ADAMS,et al. STRIATO-NIGRAL DEGENERATION. , 1964, Journal of neuropathology and experimental neurology.
[18] A. Lees,et al. Striatonigral degeneration. A clinicopathological study. , 1990, Brain : a journal of neurology.
[19] W. Koller. Alternate day levodopa therapy in parkinsonism , 1982, Neurology.
[20] A. Lang,et al. Levodopa dose‐related fluctuations in presumed olivopontocerebellar atrophy , 1986, Movement disorders : official journal of the Movement Disorder Society.
[21] A. J. Lees,et al. Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[22] A. Barbeau,et al. Six‐year results of treatment with levodopa plus benzerazide in Parkinson's disease , 1976, Neurology.
[23] C. Ward,et al. Research diagnostic criteria for Parkinson's disease. , 1990, Advances in neurology.
[24] S. Yorifuji,et al. Dopamine metabolism in the central nervous system after discontinuation of l-dopa therapy in patients with Parkinson disease , 1984, Journal of the Neurological Sciences.
[25] J. Sharpe,et al. Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation. , 1973, Journal of the neurological sciences.
[26] A. Lees,et al. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. , 1989, Journal of neurology, neurosurgery, and psychiatry.